TickerTalks
Browse all tickers →
TickerTalks›$PEPG
PEPEPG

PepGen Inc.

$PEPG·$179M·Biotechnology·Healthcare
$2.590.0%YTD-60.0%1Y-44.2%
Price updated 3h ago·X counts updated 1d ago
PEPEPG
$PEPGPepGen Inc.
$2.590.00%31 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $PEPG on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

31X posts · last 7 days
Sep 11Sep 27
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $PEPG's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Mixed sentimentAI analysisGenerated by AI from underlying data9 posts analyzed · as of 2026-09-15

Novartis's DM1 miss adds enormous risk and opportunity to PepGen — bulls argue PEPG's differentiated MOA and much better mis-splicing correction data should stand out, while skeptics say the whole DM1 space gets discounted on 'biological rationale concerns'. Read is uncertain and contested.

Read what X is saying about $PEPG

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $PEPG — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storyWinding up for a moveAI verdict · as of 2026-09-27

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

PepGen is a DM1 biotech at the 20th percentile of range — the Novartis DM1 miss creates both risk and opportunity.

PepGen is a US-listed clinical-stage biotech developing therapies for myotonic dystrophy type 1 (DM1) and other rare neuromuscular indications. The equity has been demolished 60% YTD as the entire DM1 space came under pressure.

  • There is no revenue yet: quarterly revenue was zero and the free-cash-flow yield of -42% tells you the cash burn is fast on a $179M market cap — this is a survival-timeline biotech story.
  • The valuation reflects the pressure: negative TTM earnings on essentially no revenue — the equity is 100% priced on the pipeline arriving and PPMO-based DM1 therapies working.
  • The Novartis DM1 miss is the double-edged catalyst: bulls argue PepGen's differentiated mechanism and better mis-splicing correction data should stand out, while skeptics say the whole DM1 space gets discounted on 'biological rationale concerns' — a legitimately contested read.

The Nov 11 print is the arbiter: any commentary on the FSHD or DM1 pipeline milestones plus differentiated mis-splicing correction data restarts the coil; another quarter of losses without a pipeline update or a fresh dilutive raise is the invalidation. The bull case works only if PepGen's mechanism is genuinely differentiated from what Novartis just missed on — otherwise the biological-rationale concern extends to the whole space.

Agrees with X sentimentAligned that the Novartis DM1 miss is a legitimately contested catalyst — the crowd's split between 'differentiated MOA stands out' and 'biological rationale concerns' captures the honest read; both positions are defensible.

What to watch: Nov 11 earnings — DM1 or FSHD pipeline milestones, cash-burn trajectory, and any commentary on differentiated mis-splicing correction data. Positive pipeline data extends the coil; a fresh dilutive raise or a soft pipeline update is the invalidation.

On the calendar: 2026-11-11 — Q3 earnings

Read the AI verdict on $PEPG

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing peptide-conjugated oligonucleotide therapies for Duchenne muscular dystrophy and other neuromuscular diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PEPG.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $PEPG

Neutral — Clinical-stage biotech developing peptide-conjugated oligonucleotide therapies for Duchenne muscular dystrophy and other neuromuscular diseases.

Top industry ETF

$IBBiShares Biotechnology ETF
+24.2%YTD
+48.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-56.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-41.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-51.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.26$-0.28+8.6%
Q1 2026May 12, 2026$-0.26$-0.31+16.1%
Q4 2025Mar 4, 2026$-0.27$-0.40+32.5%
Q3 2025Nov 12, 2025$-0.52$-0.63+17.5%
Next earningsWed, Nov 11·consensus EPS $-0.27

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.26$-15.8M
Q1 FY26$0———$-0.26$-18.4M
Q4 FY25$0———$-0.43$-15.8M
Q3 FY25$0———$-0.55$-19.4M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$37.5M$37.5M – $37.5M-$1.06-$1.27 – -$0.937
FY27$4.6M$4.6M – $4.6M-$1.09-$1.53 – -$0.704
FY28$31.1M$31.1M – $31.1M-$1.02-$1.69 – -$0.806
FY29$33.3M$33.3M – $33.3M-$0.89-$0.89 – -$0.894
FY30$81.8M$81.8M – $81.8M-$0.44-$0.44 – -$0.443

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.20%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-3.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-25.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 36.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 21Kasra KasraianChief Technical Officer1.2K sh$2K
+ 8 other (8 awards) in window

See when $PEPG insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

PepGen (PEPG) filed an 8-K on August 7, 2026 under Items 2.02, 7.01, and 8.01, reporting Q2 2026 financial results, furnishing Regulation FD investor materials, and disclosing other events. Body unavailable — earnings details are in Exhibit 99.1, which is not included in the excerpt. PepGen is a clinical-stage RNA therapeutics company focused on neuromuscular diseases. The combined multi-item filing is a comprehensive investor communication covering earnings, investor presentations, and any other concurrent announcements.

8-KShareholder voteJun 228-K — Item 5.07: Shareholder vote
AI summary

PepGen (PEPG) filed an 8-K on June 23, 2026 (event date June 18) under Item 5.07, reporting the results of shareholder votes at its annual meeting. Item 5.07 includes the vote tallies for each matter submitted to shareholders, typically including director elections, executive compensation (say-on-pay), and auditor ratification. The excerpt is the cover page; the specific vote outcomes are in the body. PepGen is a clinical-stage RNA therapeutics company focused on Duchenne muscular dystrophy.

8-KPress release / Reg FDMay 218-K — Item 7.01: Press release / Reg FD
S-3Shelf registrationMay 18S-3
+ 12 other (2 10-Qs · 2 13Gs · 2 proxys · 1 EFFECT) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

PepGen, Inc. $PEPG Shares Bought by Squarepoint Ops LLCdefenseworld.net·11d agoADAR1 Capital Management LLC Acquires New Shares in PepGen, Inc. $PEPGdefenseworld.net·34d agoPepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlightsgurufocus.com·54d agoPepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Reviewgurufocus.com·54d agoPepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlightsbusinesswire.com·54d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$VKTX$MRNA$RARE$NWBO$AURA$ARCT$IBRX$NKTR
Voices on X · last 7 days

No standout posts about $PEPG on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport